German guidelines for the sequential medical treatment of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs

Rheumatology International

Volumn 34, Issue 1, 2014, Pages 1-9

  Albrecht, Katinka ^a   Krüger, Klaus ^b   Wollenhaupt, Jürgen ^c   Alten, Rieke ^d   Backhaus, Marina ^d   Baerwald, Christoph ^e   Bolten, Wolfgang ^f   Braun, Jürgen ^g   Burkhardt, Harald ^h   Burmester, Gerd R ^d   Gaubitz, Markus ⁱ   Gause, Angela ^j   Gromnica Ihle, Erika ^k   Kellner, Herbert ^l   Kuipers, Jens ^m   Krause, Andreas ⁿ   Lorenz, Hans Martin ^o   Manger, Bernhard ^p   Nüßlein, Hubert ^q   Pott, Hans Georg ^r   Rubbert Roth, Andrea ^s   Schneider, Matthias ^t   Specker, Christof ^u   Schulze Koops, Hendrik ^v   Tony, Hans Peter ^w   Wassenberg, Siegfried ^x   Müller Ladner, Ulf ^y   more..

^a German Center for Rheumatology Research   (Germany)

^b Division of Rheumatology   (Germany)

^c Schoen Clinic Hamburg Eilbek   (Germany)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^e UNIVERSITY OF LEIPZIG   (Germany)

^f Klaus Miehlke Klinik   (Germany)

^g ST JOSEF HOSPITAL   (Germany)

^h GOETHE UNIVERSITY   (Germany)

ⁱ UNIVERSITY OF MÜNSTER   (Germany)

^j Centre of Rheumatology and Autoimmunology   (Germany)

^k German League Against Rheumatism   (Germany)

^l German League Against Rheumatism ^*  (Germany)

^m Red Cross Hospital   (Germany)

ⁿ Hospital Berlin Buch   (Germany)

^o UNIVERSITY OF HEIDELBERG   (Germany)

^p UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^q Rheumatology Practice   (Germany)

^r Physical Therapy and Clinical Immunology   (Germany)

^s UNIVERSITY OF COLOGNE   (Germany)

^t HEINRICH HEINE UNIVERSITY   (Germany)

^u Eye Hospital   (Germany)

^v UNIVERSITY OF MUNICH   (Germany)

^w UNIVERSITY OF WÜRZBURG   (Germany)

^x Evangelisches Fach krankenhaus Ratingen   (Germany)

^y JUSTUS LIEBIG UNIVERSITY   (Germany)

more..

Author keywords

Biologic agents; Clinical practice guideline; Disease modifying antirheumatic drugs; Glucocorticoids; Rheumatoid arthritis

Indexed keywords

ABATACEPT; ADALIMUMAB; CYCLOSPORIN A; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; FOLIC ACID; GLUCOCORTICOID; GOLIMUMAB; HYDROXYCHLOROQUINE; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; PREDNISOLONE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; SALAZOSULFAPYRIDINE; STEROID; TOCILIZUMAB; TUMOR NECROSIS FACTOR INHIBITOR;

ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL (TOPIC); DELPHI STUDY; DRUG APPROVAL; DRUG EFFICACY; GERMANY; HUMAN; MEDICAL PRACTICE; MEDICAL SOCIETY; META ANALYSIS (TOPIC); PRACTICE GUIDELINE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; RHEUMATOLOGY; SYSTEMATIC REVIEW; TREATMENT PLANNING;

ALGORITHMS; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL PRODUCTS; CONSENSUS; CRITICAL PATHWAYS; DELPHI TECHNIQUE; DRUG ADMINISTRATION SCHEDULE; DRUG SUBSTITUTION; DRUG THERAPY, COMBINATION; EVIDENCE-BASED MEDICINE; GERMANY; HUMANS; RHEUMATOLOGY; TIME FACTORS; TREATMENT OUTCOME;

EID: 84892613879     PISSN: 01728172     EISSN: 1437160X     Source Type: Journal    
DOI: 10.1007/s00296-013-2848-3     Document Type: Article

References (43)

1. Smolen JS, Landewe R, Breedveld FC et al (2010) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 69:964-975
2. Nam JL, Winthrop KL, van Vollenhoven RF et al (2010) Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA. Ann Rheum Dis 69:976-986
3. Gaujoux-Viala C, Smolen JS, Landewe R et al (2010) Current evidence for the management of rheumatoid arthritis with synthetic disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 69:1004-1009
4. Gorter SL, Bijlsma JW, Cutolo M et al (2010) Current evidence for the management of rheumatoid arthritis with glucocorticoids: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 69:1010-1014
5. Knevel R, Schoels M, Huizinga TWJ et al (2010) Current evidence for a strategic approach to the management of rheumatoid arthritis with disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 69:987-994
6. Krüger K, Wollenhaupt J, Albrecht K et al (2012) German 2012 guidelines for the sequential medical treatment of rheumatoid arthritis. Adapted EULAR recommendations and updated treatment algorithm. [Article in German]. Z Rheumatol 71:592-603
7. Albrecht K, Krüger K, Müller-Ladner U, Wollenhaupt J (2012) Systematic literature research for S1 guidelines on sequential medical treatment of rheumatoid arthritis [Article in German]. Z Rheumatol 71:604-618
8. Wollenhaupt J, Albrecht K, Krüger K, Müller-Ladner U (2013) The new 2012 German recommendations for treating rheumatoid arthritis: differences compared to the European standpoint. Z Rheumatol 72(1):6-9
9. Schoels M, Wong J, Scott DL et al (2010) Economic aspects of treatment options in rheumatoid arthritis: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 69:996-1004
10. OCEBM Levels of Evidence Working Group "The Oxford 2011 Levels of Evidence". Oxford Centre for Evidence-Based Medicine. http://www.cebm.net/ index.aspx?o=5653
11. Wollenhaupt J, Alten R, Backhaus M et al (2009) Recommendations for the treatment of rheumatoid arthritis. Results from a German consensus conferenence: update 2009 [Article in German]. Akt Rheumatol 34:234-239
12. Visser K, van der Heijde D (2009) Optimal dosage and route of administration of methotrexate in rheumatoid arthritis: a systematic review of the literature. Ann Rheum Dis 68:1094-1099
13. Tarner IH, Manger B, Fleck E et al (2009) Evidence-based recommendations of a National Group of Experts on the use of methotrexate in inflammatory rheumatic diseases [Article in German]. Akt Rheum 34:59-66
14. Bathon J, Robles M, Ximenes AC (2011) Sustained disease remission and inhibition of radiographic progression in methotrexate-naïve patients with rheumatoid arthritis and poor prognostic factors treated with abatacept: 2-year outcomes. Ann Rheum Dis 70:1949-1956
15. Smolen JS, Fleischmann R, Emery P et al (2011) The OPTIMA study of methotrexate and adalimumab: 78-week outcomes in early rheumatoid arthritis patients based on achieving a low DAS28 target after 26 weeks. Ann Rheum Dis 70(Suppl3):259
16. Soubrier M, Puéchal X, Sibilia J et al (2009) Evaluation of two strategies (initial methotrexate monotherapy vs. its combination with adalimumab) in management of early active rheumatoid arthritis: data from the GUEPARD trial. Rheumatology 48:1429-1434
17. De Boer KV, Visser K, Ronday HK et al (2010) Induction therapy with methotrexate and prednisone in rheumatoid or very early arthritic disease: IMPROVED study. Arthritis Rheum 62(Suppl10):1396
18. Klarenbeek NB, Güler-Yüksel M, van der Kooij SM et al (2011) The impact of four dynamic, goal-steered treatment strategies on the 5-year outcomes of rheumatoid arthritis patients in the BeSt study. Ann Rheum Dis 70:1039-1046
19. Hafstrem I, Albertsson K, Boonen A, van der Heijde D, Landewe R, Svensson B (2009) Remission achieved after 2 years treatment with low-dose prednisolone in addition to disease-modifying anti-rheumatic drugs in early rheumatoid arthritis is associated with reduced joint destruction still present after 4 years: an open 2-year continuation study. Ann Rheum Dis 68:508-513
20. Todoerti M, Scire CA, Boffini N et al (2010) Early disease control by low-dose prednisone comedication may affect the quality of remission in patients with early rheumatoid arthritis. Ann NY Acad Sci 1193:139-145
21. Kremer JM, Genovese MC, Cannon GW (2002) Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 137:726-733
22. O'Dell JR, Leff R, Paulsen G (2002) Treatment of rheumatoid arthritis with methotrexate and hydroxychloroquine, methotrexate and sulfasalazine, or a combination of the three medications: results of a two-year, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 46:1164-1170
23. Tugwell P, Pincus T, Yocum D et al (1995) Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis. The methotrexate-cyclosporine combination study group. N Engl J Med 333:137-141
24. Curtis JR, Yang S, Chen L et al (2012) Predicting low disease activity and remission using early treatment response to antitumour necrosis factor therapy in patients with rheumatoid arthritis: exploratory analyses from the TEMPO trial. Ann Rheum Dis 71:206-212
25. Haraoui B, Emery P, Mozaffarian N et al (2010) Change in CRP at 12 weeks predicts the risk of rapid radiographic progression at 2 years in methotrexate-treated patients with early rheumatoid arthritis. Arthritis Rheum 62(Suppl 10):110
26. Ichikawa Y, Saito T, Yamanaka H et al (2010) Clinical activity after 12 weeks of treatment with nonbiologics in early rheumatoid arthritis may predict articular destruction 2 years later. J Rheumatol 37:723-729
27. Singh JA, Christensen R, Wells GA (2009) Biologics for rheumatoid arthritis: an overview of Cochrane reviews. Cochrane Database Syst Rev 4 Wiley, Ltd, Chichester, doi: 10.1002/14651858.CD007848
28. Devine EB, Alfonso-Cristancho R, Sullivan SD (2011) Effectiveness of biologic therapies for rheumatoid arthritis: an indirect comparison approach. Pharmacotherapy 31:39-51
29. Salliot C, Finckh A, Katchamart W et al (2011) Indirect comparisons of the efficacy of biological antirheumatic agents in rheumatoid arthritis in patients with an inadequate response to conventional disease-modifying antirheumatic drugs or to an anti-tumour necrosis factor agent: a meta-analysis. Ann Rheum Dis 70:266-271
30. Dougados M, Huizinga T, Sheeran T et al (2011) Tocilizumab plus methotrexate does not have superior clinical efficacy to TCZ alone in RA patients with inadequate response to MTX: 24-week results of the ACT-RAY study. Ann Rheum Dis 70(Suppl3):73
31. Sibilia J, Graninger W, Östör A et al (2011) Comparison of tocilizumab as monotherapy or with add-on DMARDs in patients with rheumatoid arthritis and an inadequate response to previous treatments: ACT-SURE results. Ann Rheum Dis 70(Suppl3):466
32. Finckh A, Dehler S, Gabay C et al (2009) The effectiveness of leflunomide as a co-therapy of tumour necrosis factor inhibitors in rheumatoid arthritis: a population-based study. Ann Rheum Dis 68:33-39
33. Strangfeld A, Hierse F, Kekow J et al (2009) Comparative effectiveness of tumour necrosis factor alpha inhibitors in combination with either methotrexate or leflunomide. Ann Rheum Dis 68:1856-1862
34. Chatzidionysiou K, Lie E, Nasonov E et al (2012) Effectiveness of disease-modifying antirheumatic drug co-therapy with methotrexate and leflunomide in rituximab-treated rheumatoid arthritis patients: results of a 1-year follow-up study from the CERERRA collaboration. Ann Rheum Dis 71:374-377
35. Navarro-Sarrabia F, Ruiz-Montesinos D, Hernandez B et al (2009) DAS-28-based EULAR response and HAQ improvement in rheumatoid arthritis patients switching between TNF antagonists. BMJ Muskuloskelet Disord 10:91
36. Keystone E, Ogale S, Devenport J, Lepley D (2011) Benefit of continuing tocilizumab therapy (8 mg/kg every 4 weeks) in rheumatoid arthritis patients who have not responded adequately within the first 8 weeks. Ann Rheum Dis 70(Suppl3):461
37. Kievit W, Fransen J, Adang EM et al (2011) Long-term effectiveness and safety of TNF-blocking agents in daily clinical practice: results from the Dutch Rheumatoid Arthritis Monitoring register. Rheumatology 50:196-203
38. Schiff M, Beaulieu A, Scott DL, Rashford M (2010) Mycophenolate mofetil in the treatment of adults with advanced rheumatoid arthritis: three 24-week, randomized, double-blind, placebo- or ciclosporin-controlled trials. Clin Drug Investig 30:613-624
39. Tanaka Y, Takeuchi T, Mimori T et al (2010) Discontinuation of infliximab after attaining low disease activity in patients with rheumatoid arthritis: RRR (remission induction by Remicade in RA) study. Ann Rheum Dis 69:1286-1291
40. Van der Woude D, Young A, Jayakumar K et al (2009) Prevalence of and predictive factors for sustained disease-modifying antirheumatic drug-free remission in rheumatoid arthritis. Arthritis Rheum 60:2262-2271
41. O'Mahony R, Richards A, Deighton C, Scott D (2010) Withdrawal of disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: a systematic review and meta-analysis. Ann Rheum Dis 69:1823-1826
42. Tiippana-Kinnunen T, Paimela L, Kautiainen H, Laasonen L, Leirisalo-Repo M (2010) Can disease-modifying anti-rheumatic drugs be discontinued in long-standing rheumatoid arthritis? A 15-year follow-up. Scand J Rheumol 39:12-18
43. Smolen JS, Aletaha D, Koeller M, Weisman MH, Emery P (2007) New therapies for treatment of rheumatoid arthritis. Lancet 370:1861-1874